Oestrogène naturel pharmaceutique de Promestriene de matières premières de poudre blanche

Nom du produit: Promestriene

CAS: 39219-28-8

Apparence: poudre blanche

pureté: 99%

Marque déposée: Pharmalab

Original: Chine

Classe: Qualité pharmaceutique

Forfait: Colis déguisé ; Sac en aluminium

Date de livraison: 3-5 jours de travail

Certificat: ISO 9001, USP,BPF

Paiement: Western union, MoneyGram, T/T, bitcoins

Expédition: SMU,HKEMS,EUB,ETK,FEDEX,DHL,UPS,Aramex,ETC

Politique: Politique de réexpédition

MF: C22H32O2

MW: 328.49

EINECS: 254-361-6

Mp: 64-660C

température de stockage: -20°C Congélateur

Usage : A synthetic diethyl-ether of Estradiol with no distal hormonal effects, in patients undergoing surgical correction for stress urinary incontinence (SUI).

Symptoms of urogenital system caused by estrogen deficiency are common problems that impair the quality of life and sexuality. One of the most common clinical problems reported by postmenopausal women is sympathetic pain caused by vaginal atrophy.Vaginal lubricants and humectants are commonly used as first-line, non-prescription, vaginal dryness and painful treatment of sexual intercourse, but need to be used every day, only need lasting effect, can not completely relieve symptoms.Vaginal estrogen treatment of vaginal atrophy, effectively reduce the burning, itching, sexual intercourse and other symptoms. They increase the atrophic epithelial lubrication, reduce vaginal pH, and increase local glycogen. This helps to restore “normal” microvirus infections, reducing infection and inflammation.All vaginal estrogen treatment at the appropriate dose of vaginal atrophy is equally clinically effective. En réalité, one-third of postmenopausal women can benefit from the use of vaginal estrogen therapy, but the fear of systemic absorption limits its use.

Promestriene is 3-propyl and 17b-methyl ether of estradiol, which has an effective effect on vaginal atrophy and is at least absorbed.Through its long and extensive clinical experience, Promestriene safety is further confirmed. Promestriene was first introduced in France in 1974. After millions of boxes of cream and capsules sold in 34 countries around the world, there is only one hemorrhagic hemophilia in older women casereport that can be attributed to long and sustained promestriene cream treatment. Neck stenosis is caused by atrophy before the onset of topical treatment, and intrauterine hemorrhage is not associated with prostate use.

Methods In order to confirm the low absorption and safety of prostaglandins, a review of all the literature was conducted in Pubmed and Scopus; Micromedex was consulted and all related articles were searched and analyzed manually. All analytical papers are consistent with the relevant functions and safety. They are summarized in Table 1.

It causes low plasma concentrations due to less penetration into the basement membrane.Estradiol is the main intracellular human estrogen, which is more effective than estrone and estradiol at the receptor level; it is the primary estrogen secreted by menopause. Estrogen regulates pituitary secretion of luteinizing hormone (LH) and follicle stimulating hormone (FSH) by negative feedback; estrogen replacement can reduce these hormone levels.

Promestriene is a locally synthesized version of the hormone estradiol used to treat vaginal atrophy, tissue thinning and contraction caused by low estrogen levels in postmenopausal women. The symptoms of vaginal atrophy are vaginal dryness, soreness, sexual intercourse and pain during incontinence. There are few reports of side effects associated with local tolerance to trimer therapy, as a study in the Journal of Steroids notes that less than 1% of the topical application precursors are absorbed.